A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2007-05-10
• Target enrollment: 0
• Participant gender: All

Summary

The compound GW642444 has previously been found to be well tolerated with no significant side effects in subjects with asthma and healthy volunteers. This study will assess the safety and tolerability of GW642444 in subjects with COPD in order to obtain information to support dosing in a broader population of subjects with COPD

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Salmeterol Xinafoate

Criteria

Inclusion criteria:

• females must be of non-childbearing potential

• moderately severe COPD

Exclusion criteria:

• Subjects with a main diagnosis of asthma

• subjects with poorly controlled COPD

• subjects with significant heart, renal, endocrine, psychiatric, immunological or neurological disease.